The pharmacist can play a key role in the development of critical pathways for disease states with warfarin as a component of therapy. The pharmacist must be familiar with the complex therapeutic considerations involved with warfarin therapy. This paper will briefly review warfarin therapeutics and will discuss strategies for pharmacist involvement in development of critical pathways including warfarin therapy. Participation in the multidisciplinary planning of critical pathways provides an excellent opportunity to contribute to the efficient, safe, and cost-effective use of warfarin.
Get full access to this article
View all access options for this article.
References
1.
O'Reilly RA,Aggeler PM,Hoag MS.Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs.N Eng1 J Med. 1983;308:1229-1230
Hulse ML.Warfarin resistance: diagnosis and therapeutic alternatives.Pharmacotherapy. 1996;6 (6): 1009-1017
4.
Richards RK.Influence of fever upon the action of 3,3'-methylene-bis-(4-hydroxocoumarin) (dicoumarol).Science. 1943;97:313
5.
Owens JC,Neely WB,Owen WR.Effect of sodium dextrothyroxine in patients receiving anticoagulants.N Engl J Med. 1962;266:76-79
6.
Hirsh J,Dalen JE,Dyekin K.Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest. 1995;108 (suppl): 231S-246S
7.
Chow WH,Cheung KL,Ling HM.Potentiation of warfarin anticoagulation by topical methylsalicylate ointment.J Roy Soc Med. 1989;82:501-502
8.
Tam LS,Chan TYK,Leung WK.Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil.Aust NZ J Med. 1995;25:258
9.
Kiesewetter H,Jung F,Pindur G.Effects of garlic on thrombocyte aggregation, microcirculation and other risk factors.Int J Clin Pharmacol Ther Toxicol. 1991;29:151-155
10.
Hiatt J,Zablocki CJ,Wittkowsky AK.Criteria for use of warfarin in adult inpatients and outpatients.Clin Pharm. 1993;12:307-313
11.
Hull RD,Raskob GE,Rosenbloom D.Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.N Engl J Med. 1990;322:1260-1264
12.
Gallus A,Jackaman J,Tillett J.Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.Lancet. 1986;2:1293-1296
13.
Mohiuddin AM,Hillman DE,Destache CJ.Efficacy and safety of early vs late heparin therapy in acute thromboembolism.Am Heart J. 1992;23:729-732
14.
Self TH,Bauman JH,Brown JR.Concurrent initiation of heparin and warfarin therapy.Am Heart J. 1981;102:470-471
15.
Saltiel E.Critical pathway experience at Cedars-Sinai Medical Center.Am J Health-Syst Pharm. 1995;52:1063-1089
Fennerty A,Dolben J,Thomas P.Flexible induction dose regimen for warfarin and prediction of maintenance dose.Br J Med. 1984;288:1268-1270
19.
Doecke CJ,Cosh DG,Gallus AS.Standardised initial warfarin treatment: evaluation of initial treatment response and maintenance dose prediction by randomised trial, and risk factors for an excessive warfarin response.Aust NZ J Med. 1991;21:319-324
20.
Galloway MJ,Foggin JJ,Dixon S.Introduction of computer assisted control of oral anticoagulation in general practice.J Clin Pathol. 1995;48:1144-1146
21.
White RH,Mungall D.Outpatient management of warfarin therapy: comparison of computer-predicted dosage adjustment to skilled professional care.Ther Drug Monitor. 1991;13:46-50
22.
Booth SL,Pennington JA,Sadowski JA.Food sources and dietary intakes of vitamin K-1 (phylloquinone) in the American diet: data from the FDA total diet study.J Am Diet Assoc. 1996;96:149-154
23.
Lee YP,Schommer JC.Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions.Am J Health-Syst Pharm. 1996;53:1580-1583
24.
Wilt VM,Gums JG,Ahmed OL.Outcome analysis of a pharmacist-managed anticoagulation service.Pharmacotherapy. 1995;15:732-739
25.
Gray DR,Garabedian-Ruffalo SM,Gray DR.Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic.Drug Intell Clin Pharm. 1985;19:575-580
26.
Calcagno D,Pubentz M,Carey R.Improving patient satisfaction with warfarin management.Am J Man Care. 1996;2:804-810
27.
Engle JP.Anticoagulation: practice focus in an ambulatory clinic.J Pharm Pract. 1990;3:349-357
28.
Bernstein D,Harrison EC,McCarron MM.A patient profile system for monitoring long-term anticoagulant therapy.Am J Hosp Pharm. 1974;31:258-261
29.
Wiser TH,Mintzer DL.Oral anticoagulation therapy managed by pharmacy clinicians: a description with selected patient outcomes.US Pharm. 1980;14:23-32
30.
Bell CJ,Wiser TH,Kerr RA.Oral anticoagulant management by pharmacy clinicians.Contemp Pharm Pract. 1979;2:101-107
31.
Norton JLW,Gibson DL.Establishing an outpatient anticoagulation clinic in a community hospital.Am J Health-Syst Pharm. 1996;53:1151-1157
32.
Conte RR.Training and activities of pharmacist prescribers in a California pilot project.Am J Hosp Pharm. 1986;43:375-380
33.
Reinders TP,Steinke WE.Pharmacist management of anticoagulant therapy in ambulant patients.Am J Hosp Pharm. 1979;36:645-648
34.
Ellis RF,Stephens MA,Sharp GB.Evaluation of a pharmacy-managed warfarin-monitoring service to coordinate inpatient and outpatient therapy.Am J Hosp Pharm. 1992;49:387-394
35.
Saltiel E.Critial pathways: a primer for managed care pharmacists.J Managed Care Pharm. 1996;2:576-582
